President and Chief Operating Officer · Aclaris Therapeutics, Inc. (ACRS)

Hugh Davis

FY2024 is the first fiscal year CompBrief holds for Hugh Davis as a named executive officer of Aclaris Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,595,185

Salary $62,500Stock awards $423,720

1st of 4 named executive officers at Aclaris Therapeutics by FY2024 total.

4 named officers on file for Aclaris Therapeutics, FY2024

Hugh Davis’s pay file — $29

  • 1 fiscal year of pay, line by line
  • ACRS’s disclosed peer group of 43 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aclaris Therapeutics’s whole pay program stands against its peers

  • Aclaris Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ACRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Hugh Davis’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Hugh Davis compensation by year

Aclaris Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Aclaris Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$62,500
Bonus$0
Stock awards$423,720
Option awards$1,076,674
Non-equity incentive$30,625
Pension and deferred compensation$0
All other$1,666
Total$1,595,185

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aclaris Therapeutics, Inc. DEF 14A filed April 24, 2025, accession 0001558370-25-005332, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Aclaris Therapeutics, Inc. filed document, accession 0001558370-25-005332. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU107,000$265,360—
Option375,000—$3.96

Per the Outstanding Equity Awards at Fiscal Year-End table in Aclaris Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

6 Form 4 lines since the FY2024 proxy (filed April 24, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-03Exercise or conversion—18,675—45,425
2026-02-03Exercise or conversion derivative—18,675$0.0056,025
2026-02-02Grant or award derivative—336,300$0.00336,300
2026-02-02Grant or award derivative—96,100$0.0096,100
2025-12-02Exercise or conversion derivative—26,750$0.0080,250
2025-12-02Exercise or conversion—26,750—26,750

The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Aclaris Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Hugh Davis · this pagePresident and Chief Operating Officer$1,595,185
Neal WalkerInterim Chief Executive Officer$1,445,135
Kevin BalthaserChief Financial Officer$1,102,163
Douglas ManionFormer Chief Executive Officer and President$856,081

Board service

Aclaris Therapeutics board · FY2024–FY2025

How this board is paid

Company policy: Aclaris Therapeutics pays directors a $40,000 cash retainer and $320,000 in Stock Options and RSUs. As stated in Aclaris Therapeutics's FY2025 proxy.

The full Aclaris Therapeutics compensation record

free company brief

This page is one person within Aclaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Aclaris Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aclaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Hugh Davis's compensation dossier · One-time report. No refunds.